A recent study found that RCC-derived exosomes carry a new lncRNA, named lncRNA activated in RCC with sunitinib resistance (lncARSR), which enhances sunitinib resistance in RCC by the upregulation of AXL/c-MET and the activation of STAT3, AKT, and ERK signaling 16. This evidence concerns the gene MET and renal cell carcinoma.